AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22220935 — intervention group
Group type: COMPARATOR
Intervention: Warm packs (control group)
Number of subjects: 30
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 0.32 g/70 kg
Number of subjects: 10
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 0.56 g/70 kg
Number of subjects: 10
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 0.75 g/70 kg
Number of subjects: 10
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 1.0 g/70 kg
Number of subjects: 10
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 1.8 g/70 kg
Number of subjects: 10
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 2.4 g/70 kg
Number of subjects: 10
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 3.2 g/70 kg
Number of subjects: 10
Study 20526195 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB at doses of 0.32-3.2 g/70 kg
Number of subjects: 10
Study 18427285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetradecylthioacetic acid (TTA) 200 mg
Number of subjects: 18
Study 18427285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetradecylthioacetic acid (TTA) 600 mg
Number of subjects: 18
Study 18427285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetradecylthioacetic acid (TTA) 1000 mg
Number of subjects: 18
Study 16751039 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal drying (eyelid taping to prevent blinking)
Number of subjects: 17
Study 16751039 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinking freely after corneal drying
Number of subjects: 17
Study 12826549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg (Group I)
Number of subjects: 53
Study 12826549 — intervention group
Group type: COMPARATOR
Intervention: Psoas compartment block with ropivacaine 0.475% 25 mL (Group II)
Number of subjects: 53
Study 12826549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (Group I)
Number of subjects: 53
Study 12826549 — intervention group
Group type: COMPARATOR
Intervention: Psoas compartment block (Group II)
Number of subjects: 53
Study 10073440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand dishwashing liquid 1
Number of subjects: 0
Study 10073440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand dishwashing liquid 2
Number of subjects: 0
Study 10073440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand
Number of subjects: 0
Study 10073440 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant hand
Number of subjects: 0
Study 7578986 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF mouthwash (0.01, 0.1, 1.0 or 10 mcg/ml)
Number of subjects: 45
Study 7578986 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (0.1 percent albumin)
Number of subjects: 45
Study 7578986 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF mouthwash (various doses)
Number of subjects: 45
Study 2197002 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6 mg.kg‐1.hr‐1 and nitrous oxide 50% in oxygen
Number of subjects: 30
Study 2197002 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 9 mg.kg‐1.hr‐1 with 100% oxygen
Number of subjects: 30
Study 2197002 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg.kg‐1 and nitrous oxide 50% in oxygen with enflurane 1%
Number of subjects: 30
Study 439317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus gentamicin
Number of subjects: 0
Study 439317 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin sodium plus gentamicin
Number of subjects: 0
Study 439317 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin plus cephalothin
Number of subjects: 0
Study 31330198 — intervention group
Group type: EXPERIMENTAL
Intervention: 'at least 5 cm'
Number of subjects: 330
Study 31330198 — intervention group
Group type: COMPARATOR
Intervention: 'approximately 5 cm'
Number of subjects: 330
Study 31330198 — intervention group
Group type: EXPERIMENTAL
Intervention: 'hard and fast'
Number of subjects: 330
Study 31330198 — intervention group
Group type: COMPARATOR
Intervention: 'at least 5 cm' vs 'approximately 5 cm'
Number of subjects: 330
Study 31330198 — intervention group
Group type: COMPARATOR
Intervention: 'hard and fast' vs 'approximately 5 cm'
Number of subjects: 330
Study 31330198 — intervention group
Group type: EXPERIMENTAL
Intervention: 'hard and fast' vs 'at least 5 cm'
Number of subjects: 330
Study 28064172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional assessment and physical activity programme (including aerobic exercise and mixed strengthening, balance and coordination exercises)
Number of subjects: 172
Study 28064172 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 172
Study 28064172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional assessment and physical activity programme
Number of subjects: 172
Study 25413567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 11
Study 25413567 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-ambulation period
Number of subjects: 11
Study 23806096 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 15
Study 23806096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C infusion
Number of subjects: 15
Study 23806096 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of GLP-1 and Vitamin C
Number of subjects: 15
Study 23806096 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia recovery
Number of subjects: 15
Study 23806096 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia post hypoglycemia
Number of subjects: 15
Study 21790620 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help book (cognitive behavioral therapy for insomnia)
Number of subjects: 155
Study 21790620 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene advice
Number of subjects: 155
Study 19193233 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped smoking cessation intervention based on a trans‐theoretical model of change
Number of subjects: 3024
Study 19193233 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3024
Study 16750808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobedding (experimental group)
Number of subjects: 82
Study 16750808 — intervention group
Group type: COMPARATOR
Intervention: Routine care in separate beds (control group)
Number of subjects: 82
Study 16750808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 15319567 — intervention group
Group type: EXPERIMENTAL
Intervention: AC (doxorubicin and cyclophosphamide)
Number of subjects: 160
Study 15319567 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 160
Study 15319567 — intervention group
Group type: COMPARATOR
Intervention: Overall QOL (FACT-B)
Number of subjects: 160
Study 15319567 — intervention group
Group type: COMPARATOR
Intervention: Overall QOL during the first 9 months after randomization
Number of subjects: 160
Study 15319567 — intervention group
Group type: COMPARATOR
Intervention: Average QOL during treatment
Number of subjects: 160
Study 15319567 — intervention group
Group type: COMPARATOR
Intervention: Rate of recovery to baseline levels of QOL 1 year after randomization
Number of subjects: 160
Study 11488799 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 312
Study 9286887 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg rectal acetaminophen
Number of subjects: 28
Study 9286887 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg rectal acetaminophen
Number of subjects: 28
Study 9286887 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg rectal acetaminophen
Number of subjects: 28
Study 9286887 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dose of 10-15 mg/kg rectal acetaminophen
Number of subjects: 28
Study 9286887 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial dose recommendation
Number of subjects: 28
Study 8323451 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP 400 micrograms/day
Number of subjects: 17
Study 8323451 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP 800 micrograms/day
Number of subjects: 17
Study 8323451 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 800 micrograms/day
Number of subjects: 17
Study 3549010 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg single oral dose of ciprofloxacin
Number of subjects: 271
Study 3549010 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg single oral dose of ciprofloxacin
Number of subjects: 271
Study 26542332 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day rosuvastatin
Number of subjects: 85
Study 26542332 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin
Number of subjects: 85
Study 26542332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 27262225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1197
Study 27262225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1197
Study 24728623 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal treadmill test (MTT)
Number of subjects: 32
Study 24728623 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal treadmill test (SMTT)
Number of subjects: 32
Study 23523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 1135
Study 23523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1135
Study 23523089 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1135
Study 23523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (RT and Tamoxifen)
Number of subjects: 1135
Study 23523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Either adjuvant radiotherapy or tamoxifen
Number of subjects: 1135
Study 23523089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1135
Study 20434199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), 200 microg once daily
Number of subjects: 429
Study 18836092 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial strategy of pain management (n = 107) including anesthesic patch, specified vaccines, child education, parental accompaniment, and distraction with soap bubbles
Number of subjects: 239
Study 18836092 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial strategy of pain management
Number of subjects: 239
Study 18836092 — intervention group
Group type: COMPARATOR
Intervention: Usual pain management (n = 132)
Number of subjects: 239
Study 16787957 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted primary care decision-support intervention
Number of subjects: 0
Study 16787957 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 0
Study 12796608 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily
Number of subjects: 238
Study 12796608 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 40 mg daily
Number of subjects: 238
Study 10695097 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg nimesulide beta cyclodextrin
Number of subjects: 148
Study 10695097 — intervention group
Group type: COMPARATOR
Intervention: 100 mg nimesulide
Number of subjects: 148
Study 8561204 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 244
Study 8561204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 244
Study 8561204 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 244
Study 1906726 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, epirubicin and mitomycin C (FEM)
Number of subjects: 69
Study 1906726 — intervention group
Group type: COMPARATOR
Intervention: epirubicin
Number of subjects: 69
Study 7123498 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% casein hydrolysate (Amigen)
Number of subjects: 85
Study 7123498 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (D10W)
Number of subjects: 85
Study 7123498 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric 10% dextrose in water (D10W)
Number of subjects: 85
Study 31367878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chyme reinfusion
Number of subjects: 117
Study 31054846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily
Number of subjects: 17598
Study 31054846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17598
Study 30309351 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Number of subjects: 77
Study 30309351 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture technique
Number of subjects: 77
Study 25921035 — intervention group
Group type: EXPERIMENTAL
Intervention: Step training for 12 weeks
Number of subjects: 50
Study 25921035 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity (control)
Number of subjects: 50
Study 24947281 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus salivarius CUL61, Lactobacillus paracasei CUL08, Bifidobacterium animalis subspecies lactis CUL34 and Bifidobacterium bifidum CUL20; total of 10^10 organisms/day)
Number of subjects: 436
Study 24947281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 24947281 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 436
Study 22480204 — intervention group
Group type: EXPERIMENTAL
Intervention: UP446 250 mg/day
Number of subjects: 60
Study 22480204 — intervention group
Group type: EXPERIMENTAL
Intervention: UP446 500 mg/day
Number of subjects: 60
Study 22480204 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 60
Study 22480204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CMC capsule)
Number of subjects: 60
Study 21084042 — intervention group
Group type: COMPARATOR
Intervention: FPNS 200 µg
Number of subjects: 16
Study 21084042 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNS (100, 200, 400, and 800 µg)
Number of subjects: 16
Study 21084042 — intervention group
Group type: EXPERIMENTAL
Intervention: FPNS
Number of subjects: 16
Study 18059993 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented low Dye taping technique (ALD)
Number of subjects: 22
Study 18059993 — intervention group
Group type: COMPARATOR
Intervention: Control (untaped side)
Number of subjects: 22
Study 16163986 — intervention group
Group type: EXPERIMENTAL
Intervention: New community nursing model of care
Number of subjects: 56
Study 16163986 — intervention group
Group type: COMPARATOR
Intervention: Standard community nursing care
Number of subjects: 56
Study 11935150 — intervention group
Group type: EXPERIMENTAL
Intervention: NN2211 (1.25, 5.0, 7.5, 10.0, 12.5 microg/kg)
Number of subjects: 30
Study 11935150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17217034 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program for cancer risk reduction
Number of subjects: 649
Study 7745174 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding information booklet (sent to 75 mothers)
Number of subjects: 150
Study 7745174 — intervention group
Group type: COMPARATOR
Intervention: Control group (75 mothers)
Number of subjects: 150
Study 2661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20mg)
Number of subjects: 0
Study 2661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60mg)
Number of subjects: 0
Study 2661178 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80mg)
Number of subjects: 0
Study 2661178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets)
Number of subjects: 0
Study 31987565 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous shortwave diathermy (15 min of 40-60 W) with exercise
Number of subjects: 50
Study 31987565 — intervention group
Group type: COMPARATOR
Intervention: Sham diathermy with exercise
Number of subjects: 50
Study 29500615 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game (PAX) intervention
Number of subjects: 0
Study 27625308 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted print-based intervention providing personalized risk information regarding CRC screening.
Number of subjects: 574
Study 27625308 — intervention group
Group type: COMPARATOR
Intervention: General information about CRC screening (Control group).
Number of subjects: 574
Study 24944140 — intervention group
Group type: EXPERIMENTAL
Intervention: HTLEF group (EF < 50%)
Number of subjects: 82
Study 22064877 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (mean, 12.7 mg/L)
Number of subjects: 473
Study 22064877 — intervention group
Group type: COMPARATOR
Intervention: Low-iron formula (mean, 2.3 mg/L)
Number of subjects: 473
Study 19818062 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride ER 60 mg
Number of subjects: 1165
Study 19818062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study 18947289 — intervention group
Group type: COMPARATOR
Intervention: Conventional Utility/Weingart pliers
Number of subjects: 30
Study 18947289 — intervention group
Group type: EXPERIMENTAL
Intervention: New Debonding Instrument
Number of subjects: 30
Study 15764487 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 9
Study 15764487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 14754497 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for 7 days (400 mg/day)
Number of subjects: 168
Study 14754497 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole for 5 days (400 mg/day)
Number of subjects: 168
Study 14754497 — intervention group
Group type: COMPARATOR
Intervention: Albendazole for 3 days (400 mg/day)
Number of subjects: 168
Study 11509075 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy for the affected side (1 hour, 3 times a week for 6 weeks) combined with mental practice (listening to an audiotape 2 times a week, plus additional home practice)
Number of subjects: 1
Study 9433618 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSP sampling with 1% cutoff
Number of subjects: 1000
Study 9433618 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSP sampling with 2% cutoff
Number of subjects: 1000
Study 9433618 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSP sampling with 5% cutoff
Number of subjects: 1000
Study 9433618 — intervention group
Group type: COMPARATOR
Intervention: Non-EDSP families
Number of subjects: 1000
Study 8425995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitroglycerin
Number of subjects: 12
Study 8425995 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal nitroglycerin
Number of subjects: 12
Study 8425995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 3434740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine 600 micrograms
Number of subjects: 40
Study 3434740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal atropine 600 micrograms
Number of subjects: 40
Study 10295521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study 10295521 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study 10295521 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life considerations
Number of subjects: 0
Study 31369406 — intervention group
Group type: EXPERIMENTAL
Intervention: Visco-Trabeculotomy (VT)
Number of subjects: 51
Study 31369406 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (Trab-MMC)
Number of subjects: 51
Study 28131632 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56-enriched donor cell infusion after post-transplantation cyclophosphamide (PTCy)
Number of subjects: 10
Study 28131632 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients without CD56-enriched donor cell infusion)
Number of subjects: 10
Study 28131632 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56-enriched donor cell infusion after PTCy
Number of subjects: 10
Study 25373391 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg once a day
Number of subjects: 60
Study 25373391 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg once a day
Number of subjects: 60
Study 25373391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23406489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Day Acuvue Moist for Astigmatism (daily disposable toric soft lens)
Number of subjects: 200
Study 23406489 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys for Astigmatism (2-weekly replacement, re-usable toric soft lens)
Number of subjects: 200
Study 23406489 — intervention group
Group type: COMPARATOR
Intervention: 1 Day Acuvue Moist for Astigmatism and Acuvue Oasys for Astigmatism
Number of subjects: 200
Study 21829871 — intervention group
Group type: EXPERIMENTAL
Intervention: Body bath with neutral soap followed by natural drying of the umbilical cord
Number of subjects: 362
Study 21829871 — intervention group
Group type: COMPARATOR
Intervention: Alcohol 70% at each diaper change until separation and bath two days later
Number of subjects: 362
Study 19125978 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot Endo Sealer
Number of subjects: 60
Study 19125978 — intervention group
Group type: COMPARATOR
Intervention: AH Plus Jet
Number of subjects: 60
Study 19125978 — intervention group
Group type: COMPARATOR
Intervention: Pulp Canal Sealer
Number of subjects: 60
Study 19125978 — intervention group
Group type: COMPARATOR
Intervention: Control (SBF immersion)
Number of subjects: 60
Study 17722968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates
Number of subjects: 0
Study 17722968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bisphosphonates
Number of subjects: 0
Study 15559109 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous cueing (valid and invalid cues)
Number of subjects: 0
Study 15559109 — intervention group
Group type: EXPERIMENTAL
Intervention: Line motion illusion
Number of subjects: 0
Study 11124758 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g D‐tagatose added to the diet daily
Number of subjects: 6